NASH药物市场预计到2035年将超过480亿美元诺和诺德(NVO.US)和礼来(LLY.US)等公司开始布局

智通财经03-18

智通财经APP获悉，国际咨询公司Research Nester称，到2035年，全球非酒精性脂肪性肝炎(NASH)治疗市场预计将达到483亿美元。该机构称，这意味着2023年至2035年间，NASH治疗领域的年复合增长率将达到18%，2022年NASH治疗领域的收入达到52亿美元。该报告发布几天后，Madrigal制药公司(MDGL.US)获得了美国FDA批准的首个NASH治疗药物。这款名为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2420346498?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-03-18 09:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2420346498","market":"us","top_or_hot":-1,"title":"NASH药物市场预计到2035年将超过480亿美元 诺和诺德(NVO.US)和礼来(LLY.US)等公司开始布局","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，国际咨询公司Research Nester称，到2035年，全球非酒精性脂肪性肝炎(NASH)治疗市场预计将达到483亿美元。该机构称，这意味着2023年至2035年间，NASH治疗领域的年复合增长率将达到18%，2022年NASH治疗领域的收入达到52亿美元。该报告发布几天后，Madrigal制药公司(MDGL.US)获得了美国FDA批准的首个NASH治疗药物。这款名为...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1087544.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NASH药物市场预计到2035年将超过480亿美元 诺和诺德(NVO.US)和礼来(LLY.US)等公司开始布局</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNASH药物市场预计到2035年将超过480亿美元 诺和诺德(NVO.US)和礼来(LLY.US)等公司开始布局\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-18 09:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1087544.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，国际咨询公司Research Nester称，到2035年，全球非酒精性脂肪性肝炎(NASH)治疗市场预计将达到483亿美元。该机构称，这意味着2023年至2035年间，NASH治疗领域的年复合增长率将达到18%，2022年NASH治疗领域的收入达到52亿美元。该报告发布几天后，Madrigal制药公司(MDGL.US)获得了美国FDA批准的首个NASH治疗药物。这款名为...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1087544.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1087544.html","article_id":"2420346498","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2420346498","pubTimestamp":1710723600,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"然而，受地区肥胖率上升的推动，预计欧洲NASH治疗市场的年复合增长率最高，为18.6%。与此同时，今年1月，医疗保健分析公司IQVIA表示，到2030年，NASH治疗的全球市场规模将超过1000亿美元。IQV指的是低诊出率和监管部门批准所需的严格临床试验要求等因素。其中值得注意的是由诺和诺德开发的减肥疗法semaglutide。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4588":"碎股","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","NVO":"诺和诺德","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0238689110.USD":"贝莱德环球动力股票基金","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LLY":"礼来","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","BK4585":"ETF&股票定投概念","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","BK4534":"瑞士信贷持仓","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","BK4007":"制药","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","SG9999001176.USD":"United Global Healthcare Acc USD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC"},"translate_title":"NASH's drug market is expected to exceed $48 billion by 2035. Companies such as Novo Nordisk (NVO.US) and LLY.US have begun to lay out","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1,"LLY":1},"content_text":"智通财经APP获悉，国际咨询公司Research Nester称，到2035年，全球非酒精性脂肪性肝炎(NASH)治疗市场预计将达到483亿美元。该机构称，这意味着2023年至2035年间，NASH治疗领域的年复合增长率将达到18%，2022年NASH治疗领域的收入达到52亿美元。该报告发布几天后，Madrigal制药公司(MDGL.US)获得了美国FDA批准的首个NASH治疗药物。这款名为Rezdiffra的口服甲状腺激素受体(THR)激动剂将以4.7万美元的标价在美国上市，在美国，包括NASH在内的肝脏疾病的患病率正在迅速上升。NASH，目前被称为代谢功能障碍相关脂肪性肝炎(MASH)，是一种较晚期的非酒精性脂肪性肝病(NAFLD)，也是美国肝移植的主要原因Madrigal制药预计，150万美国人被诊断为NASH，肥胖和糖尿病是导致该疾病流行的因素。据Research Nester称，在NASH治疗支出不断上升的情况下，北美将产生最大份额的收入。随着对该病认识的提高，加上NAFLD病例数量的增加(估计约30%的NAFLD患者患有NASH)，预计将推动对治疗方案的需求。然而，受地区肥胖率上升的推动，预计欧洲NASH治疗市场的年复合增长率最高，为18.6%。与此同时，今年1月，医疗保健分析公司IQVIA(IQV.US)表示，到2030年，NASH治疗的全球市场规模将超过1000亿美元。然而，因为由于治疗障碍等因素，该行业仍不确定疾病负担如何转化为商业机会。IQVIA 表示:“所有解决NASH的创新者都面临着科学/临床、监管和实际障碍的艰巨组合。”IQV指的是低诊出率和监管部门批准所需的严格临床试验要求等因素。Rezdiffra已成为美国批准的首个治疗NASH的药物，而Madrigal不太可能长期享有先发优势，因为治疗领域变得拥挤，医疗需求未得到满足。据IQV称，目前有六种针对NASH的实验性疗法处于后期研究阶段。其中值得注意的是由诺和诺德(NVO.US)开发的减肥疗法semaglutide。此外，这家丹麦制药商还与吉利德(GILD.US)的两种实验性NASH药物合作测试GLP-1受体激动剂。Inventiva (IVA.US)、Galectin Therapeutics (GALT.US)和Galmed Pharmaceuticals (GLMD.US)是其他上市的药物开发商，他们利用自己的后期资产进入NASH领域。Hepion Pharmaceuticals (HEPA.US)、TERNS Pharmaceuticals (TERN.US)、Sagimet Biosciences (SGMT.US)、Viking Therapeutics (VKTX.US)和89bio (ETNB.US)等公司已经在2023年的中期NASH治疗中获得了积极的数据。今年，礼来公司(LLY.US)报告了其减重疗法tirzepatide治疗NASH成人患者的2期试验数据，Ionis Pharma (IONS.US)也报告了该疗法的2期试验数据，ION224在本周的2期试验中达到了主要目标。其他制药商，包括辉瑞(PFE.US)、阿斯利康(AZN.US)、吉利德/诺和诺德和Ascletis Pharma，都在等待今年NASH药物的显着2期数据。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2420346498"}

NASH药物市场预计到2035年将超过480亿美元 诺和诺德(NVO.US)和礼来(LLY.US)等公司开始布局

精彩评论

NASH药物市场预计到2035年将超过480亿美元诺和诺德(NVO.US)和礼来(LLY.US)等公司开始布局